A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of Two Doses of INV-202 in Patients With Diabetic Kidney Disease
Latest Information Update: 08 Jun 2026
At a glance
- Drugs Monlunabant (Primary)
- Indications Diabetic nephropathies
- Focus Therapeutic Use
- Sponsors Inversago Pharma
Most Recent Events
- 01 Jun 2026 Primary endpoint (Change in UACR from baseline to W16) has not been met.
- 01 Jun 2026 Results published in the Kidney International
- 12 Sep 2024 Status changed from active, no longer recruiting to completed.